News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alkermes plc (ALKS) Presents Data On Two Late-Stage Clinical Candidates, Aripiprazole Lauroxil And ALKS 5461, At 52nd Annual ACNP Meeting


12/9/2013 7:32:13 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Alkermes plc (NASDAQ: ALKS) today announced that data will be presented at the 52nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Hollywood, Fla., Dec. 8-12, 2013, related to the company’s two most advanced clinical candidates, aripiprazole lauroxil, a long-acting injectable treatment for schizophrenia, and ALKS 5461, a novel oral compound for the treatment of major depressive disorder (MDD). Enrollment in the phase 3 study for aripiprazole lauroxil has been completed, and ALKS 5461 is expected to enter phase 3 clinical trials in 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES